Proton Pump Inhibitors Accelerate Endothelial Senescence

Circulation Research

Volumn 118, Issue 12, 2016, Pages e36-e42

  Yepuri, Gautham ^a   Sukhovershin, Roman ^a   Nazari Shafti, Timo Z ^a   Petrascheck, Michael ^b   Ghebre, Yohannes T ^c   Cooke, John P ^a  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

aging; cardiovascular diseases; proteostasis deficiencies; proton pump inhibitors

Indexed keywords

BETA GALACTOSIDASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ESOMEPRAZOLE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; LYSOSOME ENZYME; OMEPRAZOLE; PLASMINOGEN ACTIVATOR INHIBITOR; PROTON PUMP INHIBITOR; RAP1 PROTEIN; SMAD3 PROTEIN; SUPEROXIDE; TELOMERASE; TELOMERIC REPEAT BINDING FACTOR 1; TELOMERIC REPEAT BINDING FACTOR 2; VON WILLEBRAND FACTOR;

ARTICLE; CELL AGING; ENDOTHELIAL DYSFUNCTION; HUMAN; MORBIDITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TELOMERE; TELOMERE SHORTENING; VASCULAR ENDOTHELIUM; CELL LINE; DRUG EFFECTS; ENDOTHELIUM CELL; METABOLISM; PHYSIOLOGY;

CELL AGING; CELL LINE; ENDOTHELIAL CELLS; HUMANS; PROTON PUMP INHIBITORS;

EID: 84969786563     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.116.308807     Document Type: Article

References (35)

1. Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ. 2008;336:2-3. doi: 10.1136/bmj.39406.449456.BE.
2. Shah NH, LePendu P, Bauer-Mehren A, Ghebremariam YT, Iyer SV, Marcus J, Nead KT, Cooke JP, Leeper NJ. Proton pump inhibitor usage and the risk of myocardial infarction in the general population. PLoS One. 2015;10:e0124653. doi: 10.1371/journal.pone.0124653.
3. Ghebremariam YT, LePendu P, Lee JC, Erlanson DA, Slaviero A, Shah NH, Leiper J, Cooke JP. Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine. Circulation. 2013;128:845-853. doi: 10.1161/CIRCULATIONAHA.113.003602.
4. Lazarus B, Chen Y, Wilson FP, Sang Y, Chang AR, Coresh J, Grams ME. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med. 2016;176:238-246. doi: 10.1001/ jamainternmed.2015.7193.
5. Gomm W, von Holt K, Thomé F, Broich K, Maier W, Fink A, Doblhammer G, Haenisch B. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol. 2016;73:410-416. doi: 10.1001/jamaneurol.2015.4791.
6. Shin JM, Sachs G. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep. 2008;10:528-534.
7. Shin JM, Cho YM, Sachs G. Chemistry of covalent inhibition of the gastric (H+, K+)-ATPase by proton pump inhibitors. J Am Chem Soc. 2004;126:7800-7811. doi: 10.1021/ja049607w.
8. Sachs G, Shin JM, Howden CW. Review article: the clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther. 2006;23(suppl 2):2-8. doi: 10.1111/j.1365-2036.2006.02943.x.
9. Balakrishna AM, Manimekalai MS, Grüber G. Protein-protein interactions within the ensemble, eukaryotic V-ATPase, and its concerted interactions with cellular machineries. Prog Biophys Mol Biol. 2015;119:84-93. doi: 10.1016/j.pbiomolbio.2015.05.003.
10. Fujisaki H, Oketani K, Nagakawa J, Takenaka O, Yamanishi Y. Effects of rabeprazole, a gastric proton pump inhibitor, on biliary and hepatic lysosomal enzymes in rats. Jpn J Pharmacol. 1998;76:279-288. doi: 10.1254/ jjp.76.279.
11. Goligorsky MS. Pathogenesis of endothelial cell dysfunction in chronic kidney disease: a retrospective and what the future may hold. Kidney Res Clin Pract. 2015;34:76-82. doi: 10.1016/j.krcp.2015.05.003.
12. Di Marco LY, Venneri A, Farkas E, Evans PC, Marzo A, Frangi AF. Vascular dysfunction in the pathogenesis of Alzheimer's disease - a review of endothelium-mediated mechanisms and ensuing vicious circles. Neurobiol Dis. 2015;82:593-606. doi: 10.1016/j.nbd.2015.08.014.
13. Flammer AJ, Anderson T, Celermajer DS, Creager MA, Deanfield J, Ganz P, Hamburg NM, Lüscher TF, Shechter M, Taddei S, Vita JA, Lerman A. The assessment of endothelial function: from research into clinical practice. Circulation. 2012;126:753-767. doi: 10.1161/ CIRCULATIONAHA.112.093245.
14. Ohkuma S, Poole B. Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents. Proc Natl Acad Sci U S A. 1978;75:3327-3331.
15. Liu W, Baker SS, Trinidad J, Burlingame AL, Baker RD, Forte JG, Virtuoso LP, Egilmez NK, Zhu L. Inhibition of lysosomal enzyme activities by proton pump inhibitors. J Gastroenterol. 2013;48:1343-1352. doi: 10.1007/s00535-013-0774-5.
16. Balch WE, Morimoto RI, Dillin A, Kelly JW. Adapting proteostasis for disease intervention. Science. 2008;319:916-919. doi: 10.1126/science.1141448.
17. Ben-Zvi A, Miller EA, Morimoto RI. Collapse of proteostasis represents an early molecular event in Caenorhabditis elegans aging. Proc Natl Acad Sci U S A. 2009;106:14914-14919. doi: 10.1073/pnas.0902882106.
18. Chondrogianni N, Fragoulis EG, Gonos ES. Protein degradation during aging: the lysosome-, the calpain-and the proteasome-dependent cellular proteolytic systems. Biogerontology. 2002;3:121-123.
19. Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest. 1997;100:2153-2157. doi: 10.1172/JCI119751.
20. Rajapakse AG, Yepuri G, Carvas JM, Stein S, Matter CM, Scerri I, Ruffieux J, Montani JP, Ming XF, Yang Z. Hyperactive S6K1 mediates oxidative stress and endothelial dysfunction in aging: inhibition by resveratrol. PLoS One. 2011;6:e19237. doi: 10.1371/journal.pone.0019237.
21. Cooke JP, Dzau VJ. Derangements of the nitric oxide synthase pathway, L-arginine, and cardiovascular diseases. Circulation. 1997;96:379-382.
22. Cooke JP, Losordo DW. Nitric oxide and angiogenesis. Circulation. 2002;105:2133-2135. doi: 10.1161/01.CIR.0000014928.45119.73.
23. Lähteenvuo J, Rosenzweig A. Effects of aging on angiogenesis. Circ Res. 2012;110:1252-1264. doi: 10.1161/CIRCRESAHA.111.246116.
24. Boe AE, Eren M, Murphy SB, Kamide CE, Ichimura A, Terry D, McAnally D, Smith LH, Miyata T, Vaughan DE. Plasminogen activator inhibitor-1 antagonist TM5441 attenuates Nω-nitro-L-arginine methyl ester-induced hypertension and vascular senescence. Circulation. 2013;128:2318-2324. doi: 10.1161/CIRCULATIONAHA.113.003192.
25. Fyhrquist F, Saijonmaa O, Strandberg T. The roles of senescence and telomere shortening in cardiovascular disease. Nat Rev Cardiol. 2013;10:274-283. doi: 10.1038/nrcardio.2013.30.
26. Matsushita H, Chang E, Glassford AJ, Cooke JP, Chiu CP, Tsao PS. eNOS activity is reduced in senescent human endothelial cells: Preservation by hTERT immortalization. Circ Res. 2001;89:793-798. doi: 10.1161/ hh2101.098443.
27. Ramunas J, Yakubov E, Brady JJ, Corbel SY, Holbrook C, Brandt M, Stein J, Santiago JG, Cooke JP, Blau HM. Transient delivery of modified mRNA encoding TERT rapidly extends telomeres in human cells. FASEB J. 2015;29:1930-1939. doi: 10.1096/fj.14-259531.
28. de Lange T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev. 2005;19:2100-2110. doi: 10.1101/ gad.1346005.
29. Gatica D, Chiong M, Lavandero S, Klionsky DJ. Molecular mechanisms of autophagy in the cardiovascular system. Circ Res. 2015;116:456-467. doi: 10.1161/CIRCRESAHA.114.303788.
30. NEXIUM (esomeprazole magnesium) label. http://www.accessdata.fda. gov/drugsatfda-docs/label/2014/022101s014021957s017021153s050lbl. pdf. Reference ID: 3675799. Accessed December 29, 2014.
31. Shin JM, Kim N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil. 2013;19:25-35. doi: 10.5056/jnm.2013.19.1.25.
32. Klotz U, Schwab M, Treiber G. CYP2C19 polymorphism and proton pump inhibitors. Basic Clin Pharmacol Toxicol. 2004;95:2-8. doi: 10.1111/j.1600-0773.2004.pto950102.x.
33. Fleenor BS, Marshall KD, Rippe C, Seals DR. Replicative aging induces endothelial to mesenchymal transition in human aortic endothelial cells: potential role of inflammation. J Vasc Res. 2012;49:59-64. doi: 10.1159/000329681.
34. Hohensinner PJ, Kaun C, Buchberger E, Ebenbauer B, Demyanets S, Huk I, Eppel W, Maurer G, Huber K, Wojta J. Age intrinsic loss of telomere protection via TRF1 reduction in endothelial cells. Biochim Biophys Acta. 2016;1863:360-367. doi: 10.1016/j.bbamcr.2015.11.034.
35. Ghebremariam YT, Cooke JP, Khan F, Thakker RN, Chang P, Shah NH, Nead KT, Leeper NJ. Proton pump inhibitors and vascular function: a prospective cross-over pilot study. Vasc Med. 2015;20:309-316. doi: 10.1177/1358863X14568444.